We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

Back to rankings

3 hedge funds and large institutions have $21K invested in Sucampo Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 183 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 188 → 3 (-185)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $645M → $21K (-$645M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 183

Holders
3
Holders Change
-185
Holders Change %
-98.4%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
183
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$73.1M
2
LSV Asset Management
LSV Asset Management
Illinois
-$44.4M
3
Renaissance Technologies
Renaissance Technologies
New York
-$35.1M
4
PC
Paulson & Co
New York
-$28.7M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$27.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
– -$7.33M -408,416 Closed
Capital Fund Management (CFM)
27
Capital Fund Management (CFM)
France
– -$7.23M -402,791 Closed
Millennium Management
28
Millennium Management
New York
– -$6.36M -354,276 Closed
KCM
29
Kennedy Capital Management
Missouri
– -$6.35M -353,528 Closed
TAL
30
TIG Advisors LLC
New York
– -$6.25M -348,017 Closed
Northern Trust
31
Northern Trust
Illinois
– -$6.02M -335,539 Closed
BFM
32
Boothbay Fund Management
New York
– -$5.96M -332,075 Closed
GF
33
Gabelli Funds
New York
– -$5.4M -301,015 Closed
KAM
34
Kassirer Asset Management
Ontario, Canada
– -$5.24M -291,784 Closed
CEI
35
Clark Estates Inc
New York
– -$4.89M -272,500 Closed
UBS Group
36
UBS Group
Switzerland
– -$4.73M -263,403 Closed
EGM
37
Engineers Gate Manager
New York
– -$4.7M -261,931 Closed
Goldman Sachs
38
Goldman Sachs
New York
– -$4.67M -259,941 Closed
PAM
39
Panagora Asset Management
Massachusetts
– -$4.42M -246,302 Closed
Geode Capital Management
40
Geode Capital Management
Massachusetts
– -$4.25M -236,757 Closed
Citigroup
41
Citigroup
New York
– -$4.22M -235,270 Closed
Two Sigma Advisers
42
Two Sigma Advisers
New York
– -$4.16M -231,945 Closed
Ameriprise
43
Ameriprise
Minnesota
– -$3.96M -220,630 Closed
LIM
44
Longfellow Investment Management
Massachusetts
– -$3.59M -200,000 Closed
Charles Schwab
45
Charles Schwab
California
– -$3.42M -190,531 Closed
Skandinaviska Enskilda Banken (SEB)
46
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$3.39M -188,700 Closed
Principal Financial Group
47
Principal Financial Group
Iowa
– -$3.38M -188,451 Closed
DIA
48
Dana Investment Advisors
Wisconsin
– -$3.33M -185,710 Closed
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
– -$3.16M -176,051 Closed
PCM
50
Piermont Capital Management
Missouri
– -$3.1M -172,980 Closed
1
2
3 4 5

SCMP Hedge Fund Activity: Q1 2018 in Review

3 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q1 2018, worth a combined $21K — down 100% from $645M a quarter earlier.

Sellers outnumbered buyers: 183 funds closed out of SCMP and 0 opened new positions — a net loss of 183 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $73.1M sold.

  • 3 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q1 2018, down from 188 in Q4 2017.
  • Funds reported $21K of Sucampo Pharmaceuticals, Inc. stock for Q1 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q1 2018 and 183 closed out, a net change of -183 holders.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q1 2018 was BlackRock, an estimated $73.1M sold.

Based on aggregated 13F filings for Q1 2018.